Literature DB >> 17312331

Erythropoietin: high profile, high scrutiny.

Jeffrey Crawford.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17312331     DOI: 10.1200/JCO.2006.08.8153

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

Review 1.  Erythropoietin receptor response circuits.

Authors:  Don M Wojchowski; Pradeep Sathyanarayana; Arvind Dev
Journal:  Curr Opin Hematol       Date:  2010-05       Impact factor: 3.284

Review 2.  Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects.

Authors:  Søren M Bentzen; Matthew Parliament; Joseph O Deasy; Adam Dicker; Walter J Curran; Jacqueline P Williams; Barry S Rosenstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

Review 3.  Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways.

Authors:  Kevin Wei; Frank Kuhnert; Calvin J Kuo
Journal:  J Mol Med (Berl)       Date:  2007-09-22       Impact factor: 4.599

4.  Erythropoiesis stimulating agents.

Authors:  David P Steensma
Journal:  BMJ       Date:  2007-03-31

5.  Randomized controlled trials in health technology assessment: overkill or overdue?

Authors:  Søren M Bentzen
Journal:  Radiother Oncol       Date:  2008-01-30       Impact factor: 6.280

6.  Anemia of aging: the role of chronic inflammation and cancer.

Authors:  Luigi Ferrucci; Lodovico Balducci
Journal:  Semin Hematol       Date:  2008-10       Impact factor: 3.851

7.  Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia.

Authors:  Robert E Schmidt; Dongyan Feng; Qiuling Wang; Karen G Green; Lisa L Snipes; Michael Yamin; Michael Brines
Journal:  Exp Neurol       Date:  2011-08-18       Impact factor: 5.330

8.  Dose reduction of epoetin-alpha in the prevention of chemotherapy-induced anaemia.

Authors:  François Lüthi; Miklos Pless; Serge Leyvraz; Beat Biedermann; Emilie Müller; Richard Hermann; Christian Monnerat
Journal:  Support Care Cancer       Date:  2009-11-17       Impact factor: 3.603

9.  Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice.

Authors:  Robert E Schmidt; Karen G Green; Dongyan Feng; Denise A Dorsey; Curtis A Parvin; Jin-Moo Lee; Qinlgi Xiao; Michael Brines
Journal:  Exp Neurol       Date:  2007-10-29       Impact factor: 5.330

10.  Erythropoietin increases macrophage-mediated T cell suppression.

Authors:  Michelle A Wood; Naomi Goldman; Kelley DePierri; John Somerville; James E Riggs
Journal:  Cell Immunol       Date:  2016-05-27       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.